A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506235-15-00

Acronym

20230016

Enrollment

145

Registered

2024-06-03

Start date

2024-11-07

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Limited-Stage Small-Cell Lung Cancer (LS SCLC)

Brief summary

PFS (BICR), OS

Detailed description

PFS (investigator), OR, DC and DOR, "PFS and OS rate at 6 months, 1 and 2 years from randomization. OS rate at 6 months, 1 year, 2 years and 3 years from randomization. TTP ", Incidence of treatment-emergent adverse events after randomization, Serum concentration of tarlatamab, Incidence of anti-tarlatamab antibody formation

Interventions

DRUGTarlatamab

DRUGELECTROLYTES

DRUGTOCILIZUMAB

DRUGVASOPRESSIN (ARGIPRESSIN)

DRUGDEXAMETHASONE

DRUGPARACETAMOL

DRUGSILTUXIMAB

DRUGPREDNISOLONE

DRUGPlacebo for Tarlatamab (AMG-757)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS (BICR), OS	—

Secondary

Measure	Time frame
PFS (investigator), OR, DC and DOR, "PFS and OS rate at 6 months, 1 and 2 years from randomization. OS rate at 6 months, 1 year, 2 years and 3 years from randomization. TTP ", Incidence of treatment-emergent adverse events after randomization, Serum concentration of tarlatamab, Incidence of anti-tarlatamab antibody formation	—

Countries

Austria, Belgium, Bulgaria, France, Germany, Greece, Italy, Poland, Portugal, Romania, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026